Results 11 to 20 of about 21,587 (248)
Annals of Hepatology, 2003 Hepatorenal syndrome is complication of advanced cirrhosis characterized by renal failure, changes in systemic blood pressure, and increased activity of endogenous vasoactive systems.
Andrés Cárdenas, M.D. +1 more
doaj +7 more sources
Počki, 2014 Lecture "Hepatorenal syndrome" is recommended for postgraduate education for nephrologists, physicians and general practitioners.
O.I. Taran
doaj +4 more sources
Korean J Gastroenterol, 2023 Hepatorenal syndrome (HRS) is a critical and potentially life-threatening complication of advanced liver disease, including cirrhosis. It is characterized by the development of renal dysfunction in the absence of underlying structural kidney pathology.
Choi JC, Yoo JJ.
europepmc +3 more sources
Hepatorenal syndrome: an update [PDF]
São Paulo Medical Journal, 2007 Hepatorenal syndrome (HRS) is the development of renal failure in patients with chronic previous liver disease, without clinical or laboratory evidence of previous kidney disease.
Tércio Genzini +1 more
doaj +4 more sources
Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. [PDF]
Liver IntABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Rockey DC +7 more
europepmc +2 more sources
Clinical Journal of the American Society of Nephrology, 2019 Hepatorenal syndrome is a severe complication of end-stage cirrhosis characterized by increased splanchnic blood flow, hyperdynamic state, a state of decreased central volume, activation of vasoconstrictor systems, and extreme kidney vasoconstriction leading to decreased GFR. The contribution of systemic inflammation, a key feature of cirrhosis, in the
Claire, Francoz +4 more
openaire +2 more sources
Contemporary management of pain in cirrhosis: Toward precision therapy for pain
Hepatology, EarlyView., 2022 Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman +4 more
wiley +1 more source
Hepatology, EarlyView., 2022 Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran +17 more
wiley +1 more source
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS
Hepatology, EarlyView., 2022 The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.
Alexander Queck +14 more
wiley +1 more source
Hepatology, EarlyView., 2022 Diagnostic and prognostic ability of urinary NGAL in patients with cirrhosis and AKI. Abstract Background and Aims Acute kidney injury (AKI) commonly occurs in patients with decompensated cirrhosis. Urinary neutrophil gelatinase–associated lipocalin (uNGAL) could help discriminate between different etiologies of AKI.
Carmine Gambino +14 more
wiley +1 more source